PEGS Boston August 31-September 4| Virtual
Discovery on Target September 17-19 | Virtual
BIO Japan October 14-16| Virtual
Structural basis of a potent human monoclonal antibody against Zika virus targeting a quaternary epitopePNAS, 2019
Human antibody response to Zika targets type-specific quaternary structure epitopesPLOS Pathogens, 2019
COVID-19 Update 6/25/20
The laboratories at Integral Molecular are presently operating in a modified capacity to ensure the well-being of our staff and community. Our current operations focus on customer projects and research to combat COVID-19. To learn more about our response efforts or to view our webinar, "SARS-CoV-2 Reporter Virus for Neutralization Assays" click below.
Why Are There So Few Therapeutic Antibodies Against Complex Membrane Proteins?
Multi-spanning membrane proteins are targets of half of all small molecule drugs but only 3 therapeutic monoclonal antibodies (MAbs).
MAbs offer therapeutic advantages of exquisite specificity, safety, and bioavailability and are twice as likely as small molecules to succeed in clinical trials. However, due to the complex structure and high homology of membrane protein targets, MAbs against them are difficult to generate, isolate and characterize.
Integral Molecular Enables Membrane Protein Antibody Discovery
With a 95% success rate, Integral Molecular is the leader in isolating MAbs against complex membrane proteins, including GPCRs, ion channels, transporters and viral proteins.
With 15+ years experience, Integral Molecular is the industry leader in isolating and characterizing complex membrane proteins.
Integral Molecular’s technologies have contributed to scientific discoveries featured in 200+ peer-reviewed publications.
Your success is crucial to us. We work hard to understand your needs, and strive to exceed your expectations.